Masthead and Table of Contents
Decision making in the face of uncertainty
Zika virus and blood transfusion
Relative analytical sensitivity of donor nucleic acid amplification technology screening and diagnostic real‐time polymerase chain reaction assays for detection of Zika virus RNA
Harmonization of nucleic acid testing for Zika virus
First Zika‐positive donations in the continental United States
First cases of Zika virus–infected US blood donors outside states with areas of active transmission
Amustaline (S‐303) treatment inactivates high levels of Zika virus in red blood cell components
Inactivation and removal of Zika virus during manufacture of plasma‐derived medicinal products
Zika virus is not thermostable
Inactivation of Zika virus by solvent/detergent treatment of human plasma and other plasma‐derived products and pasteurization of human serum albumin
Risk of exposure to blood products during pregnancy
Usefulness of nucleic acid testing to reduce risk of hepatitis B virus transfusion‐transmitted infection in Argentina
A comparison of methods for estimating the incidence of human immunodeficiency virus infection in repeat blood donors
The characteristics of hepatitis B surface antigen (HBsAg)‐negative hepatitis B virus (HBV) infection in Chinese blood donors
A mathematical model for estimating residual transmission risk of occult hepatitis B virus infection with different blood safety scenarios
A probable case of West Nile virus transfusion transmission
Characterization of hepatitis B virus (HBV) preS/S gene mutations in blood donors with occult HBV infection in the Baoji area of North China